Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome

Addiction

Volumn 106, Issue 3, 2011, Pages 574-580

  Kraft, Walter K ^a   Dysart, Kevin ^a,b   Greenspan, Jay S ^a,b   Gibson, Eric ^a,b   Kaltenbach, Karol ^a   Ehrlich, Michelle E ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Morphine; Neonatal abstinence syndrome; Pediatric; Sublingual drug administration

Indexed keywords

BUPRENORPHINE; HYPNOTIC SEDATIVE AGENT; MORPHINE; NARCOTIC ANTAGONIST; PHENOBARBITAL;

ADULT; ARTICLE; BIRTH WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; FEMALE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MALE; METHODOLOGY; NEWBORN; OPIATE SUBSTITUTION TREATMENT; PHASE 1 CLINICAL TRIAL; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; STATISTICS; SUBLINGUAL DRUG ADMINISTRATION; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADMINISTRATION, SUBLINGUAL; ADULT; BIRTH WEIGHT; BUPRENORPHINE; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INFANT, NEWBORN; LENGTH OF STAY; MALE; MORPHINE; NARCOTIC ANTAGONISTS; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; PHENOBARBITAL; PREGNANCY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79551634885     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.03170.x     Document Type: Article

References (27)

1. American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. Pediatrics 1998; 101: 1079-88.
2. Crocetti M. T., Amin D. D., Jansson L. M. Variability in the evaluation and management of opiate-exposed newborns in Maryland. Clin Pediatr (Phila) 2007; 46: 632-5.
3. Nandakumar N., Sankar V. S. What is the best evidence based management of neonatal abstinence syndrome? Arch Dis Child Fetal Neonatal Ed 2006; 91: F463.
4. Sarkar S., Donn S. M. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol 2006; 26: 15-17.
5. Osborn D. A., Jeffery H. E., Cole M. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2005; issue 3 CD002059.
6. Osborn D. A., Jeffery H. E., Cole M. J. Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2005; issue 3 CD002053.
7. Johnson K., Gerada C., Greenough A. Treatment of neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed 2003; 88: F2-5.
8. Jansson L. M., Velez M., Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009; 5: 47-55.
9. Lainwala S., Brown E. R., Weinschenk N. P., Blackwell M. T., Hagadorn J. I. A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. Adv Neonatal Care 2005; 5: 265-72.
10. Langenfeld S., Birkenfeld L., Herkenrath P., Muller C., Hellmich M., Theisohn M. Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug Alcohol Depend 2005; 77: 31-6.
11. Coyle M. G., Ferguson A., Lagasse L., Oh W., Lester B. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr 2002; 140: 561-4.
12. Dryden C., Young D., Hepburn M., Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. Br J Obstet Gynaecol 2009; 116: 665-71.
13. Colombini N., Elias R., Busuttil M., Dubuc M., Einaudi M. A., Bues-Charbit M. Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone. Pharm World Sci 2008; 30: 227-34.
14. Seligman N. S., Salva N., Hayes E. J., Dysart K. C., Pequignot E. C., Baxter J. K. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008; 199: 396, e1-7.
15. Oei J., Feller J. M., Lui K. Coordinated outpatient care of the narcotic-dependent infant. J Paediatr Child Health 2001; 37: 266-70.
16. Kraft W. K., Gibson E., Dysart K., Damle V. S., Larusso J. L., Greenspan J. S. etal. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics 2008; 122: e601-7.
17. Jones H. E., Johnson R. E., Jasinski D. R., O'Grady K. E., Chisholm C. A., Choo R. E. etal. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79: 1-10.
18. Finnegan L. P., Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman R. A., Friedman S. B., Nelson N., Seidel H. M., editors. Primary Pediatric Care, 2nd edn. St Louis: Mosby; 1992, p. 1367-78.
19. O'Grady M. J., Hopewell J., White M. J. Management of neonatal abstinence syndrome: a national survey and review of practice. Arch Dis Child Fetal Neonatal Ed 2009; 94: F249-52.
20. Mamelle N., Cochet V., Claris O. Definition of fetal growth restriction according to constitutional growth potential. Biol Neonate 2001; 80: 277-85.
21. Jackson L., Ting A., McKay S., Galea P., Skeoch C. A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed 2004; 89: F300-4.
22. Abdel-Latif M. E., Pinner J., Clews S., Cooke F., Lui K., Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 2006; 117: e1163-9.
23. Coghlan D., Milner M., Clarke T., Lambert I., McDermott C., McNally M. etal. Neonatal abstinence syndrome. Ir Med J 1999; 92: 232-3, 236.
24. Sutton L. R., Hinderliter S. A. Diazepam abuse in pregnant women on methadone maintenance. Implications for the neonate. Clin Pediatr (Phila) 1990; 29: 108-11.
25. Dysart K., Hsieh H. C., Kaltenbach K., Greenspan J. S. Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. J Perinat Med 2007; 35: 344-6.
26. Agthe A. G., Kim G. R., Mathias K. B., Hendrix C. W., Chavez-Valdez R., Jansson L. etal. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics 2009; 123: e849-56.
27. Blaser A., Pulzer F., Knupfer M., Robel-Tillig E., Vogtmann C., Nickel P. etal. Drug withdrawal in newborns-clinical data of 49 infants with intrauterine drug exposure: what should be done? Klin Padiatr 2008; 220: 308-15.